Trading in Grail (GRAL) stock remained halted late Wednesday as a Food and Drug Administration panel issued a mixed vote in favor of the company's blood screening test for cancer. The meeting is a key step toward FDA approval for the test, Galleri, which aims to screen asymptomatic people for myriad cancers. In general, it's easier to treat an earlier-stage…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8